Practice 14 structured short- and long-answer medical questions on CLINICAL BIOCHEMISTRY LAQs & SAQs. Review model answers for exam revision.
Answer: **TIME:** 2 HOURS GOOD LUCK DAKTARI Sample Handling in Clinical Diagnosis ## **Explain the Concept of Sample Handling in Clinical Diagnosis (5 Marks)** **Definition:** Collection, processing, and storage of biological specimens to ensure accurate laboratory results. --- ## **1. Blood Sample Types & Additives (1 mark)** - **Serum** (clotted blood) → no fibrinogen - **Plasma** (anticoagulated) → contains fibrinogen - **Heparin** - blocks clotting factors - **EDTA/Citrate** - bind Ca²⁺ - **Note:** Use serum for Na⁺, K⁺, Li⁺ (anticoagulants interfere) --- ## **2. Special Tubes (1 mark)** - **Fluoride tube** → glucose (stops glycolysis) - **Urine additives:**Azide/toluene → prevent bacteria - HCl → Ca²⁺, Mg²⁺, phosphate(prevents precipitation). - Alkaline → urate --- ## **3. Avoid Contamination (1 mark)** - No drip arm sampling - Correct tube selection - Proper labeling --- ## **4. Timely Separation (1 mark)** - Separate within 12 hours - Delayed = false high K⁺, phosphate, LDH - Hemolysis → red serum --- ## **5. Labile Analytes (1 mark)** - **Blood gases** → anaerobic + ice to prevent gas loss and lactic acid formation. - **Peptide hormones** → protease inhibitors - **Ammonia** → immediate analysis due to **glutamine breakdown** --- ## **Key Points:** Time-sensitive processing essential Proper handling = accurate results Wrong technique = wrong diagnosis **Definition:** - These are the ranges of values from which the clinical parameters are measured from **Significance:** - **Aid in diagnosis** – Compare patient results to normal limits. - **Monitor treatment** – Track changes during therapy. - **Detect disease early** – Identify abnormalities before symptoms appear. --- --- ### **Preanalytical Phase – Key Steps (Short Notes)** - **Preparation for Collection**Patient instructions: **diet, posture, urine containers**. - **Sampling Preparation****Test request**, data entry, and **tube labeling**. - **Sampling****Patient ID**, timing, tourniquet use, site & needle positioning, tube changes. - **Transport****Prompt collection** and **safe transport** to lab. - **Sample Treatment****Registration, centrifugation**, mixing, and **sample extraction**. - **Storage**Control of **storage time, temperature**, and **remixing before use**. --- --- ### **Explain Ways to Detect Systematic Errors** *(4 Marks)* - **Method Comparison** Compare results from **two different analytical methods**; significant differences suggest a systematic error. - **Standard Value Comparison** Compare **experimental result** with a **known standard value**; deviation indicates possible error. - **Use of Blank Solution** Run a **blank** (no analyte). If it gives a reading, subtract it from the result to correct for systematic error. - **Inter-Laboratory Testing** Analyze **same sample in different labs or by different analysts**; consistent differences suggest systematic error. --- o Unlabelled sample o Mislabeled sample – any mismatch or discrepancy of identification o Insufficiently labeled sample – less than two identifiers o Transfusion labeling requirements – no collector signature, no time and date of collection**** o Sample suspected to be from wrong patient – wrong blood in tube **Causes of Low Total Protein in Blood** - **Liver disease** – the liver makes most blood proteins. - **Poor diet (malnutrition)** – not enough building blocks to make proteins. - **Too much water in blood (haemodilution)** – proteins get diluted. - **Loss of key proteins** – like **albumin** or **antibodies** (globulins). (**hypoalbuminaemia** or **hypogammaglobulinaemia**.) #### **Examples of Tumor Markers:** - **Enzymes** – general, not specific to one cancer type. - **Acid Phosphatase** – seen in **prostate cancer**. - **Alkaline Phosphatase** – associated with **bone and liver cancers**. - **Prostate Specific Antigen (PSA)** – specific for **prostate cancer**. - **Alpha-Fetoprotein (AFP)** – marker for **liver cancer**. - **Immunoglobulins** – elevated in **plasma cell cancers** (e.g. multiple myeloma). - **Carbohydrate Antigen 125 (CA-125)** – seen in **ovarian cancer**. - **Carbohydrate Antigen 15-3 (CA 15-3)** – used in **breast cancer** monitoring. - **Isoenzyme Analysis**: Separate enzyme isoforms to identify the specific tissue source. - **Use of Specific Inhibitors**: Apply enzyme inhibitors that target particular isoenzymes, improving specificity. - **Glycolysis**:Main energy source, anaerobic. - Glucose → 2 ATP and lactate (no mitochondria). - **Hexose Monophosphate Shunt (Pentose Phosphate Pathway)**:Produces **NADPH** to protect against oxidative stress. - Maintains cell integrity. - **Lactate Production**:Final product of glycolysis. - Transported to liver (Cori Cycle) to produce glucose. - **No Mitochondria**: Erythrocytes cannot perform oxidative phosphorylation, relying solely on glycolysis for ATP. - **Bilirubin Metabolism**:**Heme** → **Biliverdin** → **Bilirubin** → Conjugated in liver → Excreted as bile. - **Unconjugated**: Bound to albumin (not water-soluble). - **Conjugated**: Water-soluble, excreted in bile. - **Disorders**:**Jaundice**: Yellowing of skin/sclera.**Pre-hepatic (Hemolytic)**: Excess RBC breakdown. - **Hepatic**: Liver dysfunction (e.g., hepatitis). - **Post-hepatic (Obstructive)**: Blockage in bile flow (e.g., gallstones). - **Gilbert’s Syndrome**: Mild, reduced conjugation (asymptomatic, mild jaundice under stress). - **Crigler-Najjar Syndrome**: Severe conjugation deficiency, high unconjugated bilirubin (risk of brain damage). - **Dubin-Johnson Syndrome**: Impaired excretion of conjugated bilirubin, mild jaundice. - **Clinical Tests**:**Total Bilirubin**: Conjugated + Unconjugated. - **Direct Bilirubin**: Conjugated. - **Indirect Bilirubin**: Unconjugated. **others** **Bilirubin Metabolism**: Bilirubin is a breakdown product of **heme**, released from hemoglobin in aged red blood cells. **Process**: - **Heme Breakdown**: The heme group is first converted to **biliverdin** (green) by **heme oxygenase**, then biliverdin is reduced to **bilirubin** (yellow) by **biliverdin reductase**. - **Transport to Liver**: Bilirubin is transported to the liver bound to albumin in an **unconjugated form** (indirect bilirubin). - **Conjugation in Liver**: In the liver, **UDP-glucuronosyltransferase** conjugates bilirubin with **glucuronic acid** to form **conjugated bilirubin** (direct bilirubin), which is water-soluble. - **Excretion**: Conjugated bilirubin is excreted into the bile and stored in the gallbladder, eventually being excreted in the **feces** as **stercobilin**. A small amount is reabsorbed into the blood and excreted in urine as **urobilinogen**. **Disorders of Bilirubin Metabolism**: - **Jaundice**: A clinical manifestation of excessive bilirubin in the blood, resulting in yellowing of the skin and sclera. Jaundice can be:**Pre-hepatic (Hemolytic Jaundice)**: Due to excessive breakdown of red blood cells, leading to an overproduction of bilirubin. - **Hepatic Jaundice**: Caused by liver dysfunction (e.g., hepatitis, cirrhosis) that impairs conjugation of bilirubin. - **Post-hepatic (Obstructive Jaundice)**: Due to obstruction of bile flow (e.g., gallstones, tumors), preventing the excretion of conjugated bilirubin. - **Gilbert's Syndrome**:A mild, inherited disorder resulting in reduced conjugation of bilirubin due to a genetic deficiency in **UDP-glucuronosyltransferase**. - **Clinical Significance**: Often asymptomatic but can result in mild jaundice under stress, fasting, or illness. - **Crigler-Najjar Syndrome**:A rare genetic disorder characterized by a severe deficiency or absence of **UDP-glucuronosyltransferase**, leading to the accumulation of **unconjugated bilirubin** in the blood. - **Clinical Significance**: Can lead to kernicterus (brain damage) if untreated. - **Dubin-Johnson Syndrome**:An inherited disorder where there is impaired excretion of conjugated bilirubin due to a defect in the **multidrug resistance protein 2 (MRP2)**, which is responsible for transporting conjugated bilirubin into bile. - **Clinical Significance**: Results in conjugated hyperbilirubinemia and mild jaundice, but usually no significant long-term effects. **Clinical Tests**: - **Total Bilirubin**: The sum of conjugated and unconjugated bilirubin. - **Direct Bilirubin**: Measures conjugated bilirubin. - **Indirect Bilirubin**: Measures unconjugated bilirubin. - Elevated total bilirubin, particularly unconjugated bilirubin, suggests hemolytic conditions, while elevated conjugated bilirubin points to liver or biliary tract disorders. **Metabolism of Glucose in the Eye (5 Marks)** - **Primary Energy Source**:Glucose is the *main energy substrate* for all eye tissues, especially the retina, lens, and cornea. - **Pathways Involved**:**Anaerobic Glycolysis** (major):Cornea and lens lack mitochondria; ~80% of glucose is metabolized anaerobically. - Produces lactate → diffuses into aqueous humor. - **Aerobic Glycolysis** (minor):Occurs in the retina and pigment epithelium where mitochondria are present. - Yields more ATP than anaerobic glycolysis. - **Pentose Phosphate Pathway (PPP)**:Important in lens and cornea. - Generates NADPH → protects against oxidative stress and helps maintain glutathione levels. - **Sorbitol Pathway (Polyol Pathway)**:In hyperglycemia, excess glucose is converted to sorbitol by aldose reductase. - Sorbitol accumulates → causes osmotic stress → contributes to diabetic cataracts and retinopathy. - **Importance of Glucose Metabolism**:Maintains **transparency** of lens and cornea. - Supports **retinal photoreceptors** and nerve conduction. - Generates **NADPH** for antioxidant defense. **Blood Supply of the Brain & Its Importance in Nutrient Metabolism (5 Marks)** - **Sources of Blood Supply**:**Internal Carotid Arteries** (anterior circulation). - **Vertebral Arteries** → join to form **Basilar Artery** (posterior circulation). - These form the **Circle of Willis**, ensuring collateral circulation. - **Key Vessels**:**Middle Cerebral Artery (MCA)** – major supplier of cerebral cortex. - **Anterior Cerebral Artery (ACA)** – supplies frontal lobes. - **Posterior Cerebral Artery (PCA)** – supplies occipital lobes. - **Importance in Nutrient Metabolism**:Brain depends **entirely on glucose** and oxygen; no energy stores. - Continuous blood flow is essential to deliver:**Glucose** (via GLUT-1 transporters across the blood-brain barrier). - **Oxygen** for oxidative phosphorylation. - Disruption (e.g., stroke) → leads to **hypoxia and energy failure** within minutes. - **Neurovascular Coupling**:Active neurons increase local blood flow to match metabolic demand. - Blood flow regulates delivery of metabolic substrates and clearance of CO₂ and lactate. - **Clinical Relevance**:**Ischemia** impairs glucose and oxygen delivery → rapid cell death. - Understanding vascular territories is key in **stroke localization and management**. - **Definition**:A rare **autosomal recessive disorder** affecting **hepatic excretion of conjugated bilirubin**. - **Cause**:Mutation in **MRP2 gene (ABCC2)** → defective transport protein → **impaired secretion of conjugated bilirubin** into bile. - **Key Features**:**Chronic or intermittent jaundice**. - **Dark pigmentation of the liver** (due to pigment accumulation—*melanin-like*). - Normal liver enzymes except **elevated conjugated (direct) bilirubin**. - **Diagnosis**:**High direct bilirubin** with no evidence of liver damage. - Liver biopsy: **black-colored liver** due to pigment granules. - Normal urinary coproporphyrin I:III ratio is reversed (↑ type I). - **Complications**:Generally **benign**, but may worsen with **pregnancy**, **oral contraceptives**, or **illness**. - Rare risk of **cholestasis** or **misdiagnosis as obstructive jaundice**. - **Diabetes Insipidus (DI)**:**Deficiency** or **resistance** to ADH. - Results in **polyuria**, **polydipsia**, and **dilute urine**. - Types:*Central DI* – ↓ ADH production (e.g., hypothalamic/pituitary damage). - *Nephrogenic DI* – kidneys unresponsive to ADH. - **Syndrome of Inappropriate ADH Secretion (SIADH)**:**Excess ADH secretion** → water retention → **hyponatremia**, ↓ plasma osmolality. - Causes: CNS disorders, malignancies (e.g., small cell lung cancer), drugs. - **Unexplained Acute or Chronic Kidney Disease**To determine the underlying **glomerular or interstitial pathology**. - **Nephrotic Syndrome or Proteinuria**Especially when persistent or with hematuria → may indicate **glomerulonephritis** or **amyloidosis**. - **Suspected Kidney Transplant Rejection**To confirm and **classify type of rejection** for proper treatment. - **Medical Therapy**:**Hyperthyroidism**: antithyroid drugs (e.g., *carbimazole*, *methimazole*, *PTU*). - **Hypothyroidism**: hormone replacement with **levothyroxine**. - **Surgical and Radioactive Management**:**Thyroidectomy**: for large goiters, suspicious nodules, or cancer. - **Radioiodine therapy**: destroys hyperfunctioning thyroid tissue. - **Glucagonoma**:Rare pancreatic tumor → glucagon excess → diagnosed via **elevated glucagon levels** post-stimulation. - **Hypoglycemia due to Insulinoma**:Glucagon increases blood glucose; **failure to rise** indicates **excess insulin**. - **Assessment of Pituitary or Adrenal Reserve**:Used in dynamic testing for **GH or ACTH deficiency** (glucagon stimulates GH and cortisol secretion). **Enzymes** are essential biomarkers in clinical biochemistry used for **diagnosis, monitoring, and prognosis** of various diseases. Their levels in blood or body fluids reflect tissue damage or disease activity. **1. Cardiac Enzymes – Diagnosis of Myocardial Infarction** - **Creatine Kinase-MB (CK-MB)**: Elevated within 4–6 hrs post-infarction. - **Troponins (cTnI, cTnT)**: Highly specific; gold standard for MI diagnosis. - **Lactate Dehydrogenase (LDH)**: LDH-1 > LDH-2 indicates cardiac damage. *Ref: Burtis et al., Tietz Textbook of Clinical Chemistry and Molecular Diagnostics, 6th ed.* **2. Liver Enzymes – Hepatic Injury and Obstruction** - **Alanine aminotransferase (ALT)**: Marker of hepatocellular injury. - **Aspartate aminotransferase (AST)**: Less specific, also elevated in cardiac/muscle damage. - **Alkaline phosphatase (ALP)** & **γ-glutamyl transferase (GGT)**: Elevated in biliary obstruction. *Ref: Bishop et al., Clinical Chemistry: Principles, Techniques, and Correlations, 9th ed.* **3. Pancreatic Enzymes – Pancreatitis Diagnosis** - **Amylase** and **lipase** are key indicators. - **Lipase** is more specific and remains elevated longer. *Ref: Henry's Clinical Diagnosis and Management by Laboratory Methods, 23rd ed.* **4. Enzymes in Cancer – Tumor Markers** - **Prostate-specific antigen (PSA)** – prostate cancer. - **Acid phosphatase (ACP)** – metastatic prostate cancer. - **Alkaline phosphatase (ALP)** – bone metastasis or hepatocellular carcinoma. *Ref: McPherson & Pincus, Henry's Clinical Diagnosis, 23rd ed.* **5. Inborn Errors of Metabolism – Enzyme Deficiency Disorders** - Enzyme assays help detect **genetic metabolic disorders**, e.g.:**G6PD deficiency** → hemolytic anemia. - **Phenylalanine hydroxylase deficiency** → phenylketonuria (PKU). - Use of dried blood spots in newborn screening. *Ref: Clarke & Dufour, Contemporary Practice in Clinical Chemistry, 2nd ed.* **Definition** - Non-shivering thermogenesis (NST) is **heat production without muscle activity**, primarily via **brown adipose tissue (BAT)**. **Mechanism** - Triggered by **cold exposure**. - **Hypothalamus stimulates sympathetic nervous system** → release of **norepinephrine** → activates **uncoupling protein-1 (UCP1)** in brown fat mitochondria → generates **heat instead of ATP**. **Location of Brown Fat in Newborns** - Found around:**Scapula**, **neck**, **axilla**, **kidneys**, **along spine**. **Importance in Newborns** - **Compensates for high surface area-to-volume ratio**: Reduces heat loss. - **Absent shivering mechanism**: NST is the primary heat source. - **Maintains body temperature**: Prevents **hypothermia**, which can lead to **metabolic acidosis**, **respiratory distress**, and **death**. - **Supports survival in cold extra-uterine environment**. - **Enhances oxygen and glucose utilization**: Thermogenesis is energy-demanding → closely linked with neonatal metabolism. **Clinical Relevance** - Preterm infants have **less brown fat** → higher risk of hypothermia. - Management: **incubators**, **skin-to-skin contact**, and **warm environments** help maintain thermoregulation.
Answer: - Kidneys receive ~20–25% of cardiac output. - High oxygen consumption, mainly for **active transport (Na⁺ reabsorption)**.
Answer: - **Renal cortex** performs **gluconeogenesis**, especially during fasting. - Uses **lactate, glutamine, glycerol** as substrates. - Plays a key role in **acid-base balance** via glutamine metabolism → generates **NH₃** and **bicarbonate**.
Answer: - Major energy source in **renal cortex**. - Mitochondrial β-oxidation supports ATP for sodium-potassium pumps.
Answer: - Occurs in **renal medulla** due to low oxygen tension. - Provides energy for loop of Henle and collecting ducts.
Answer: - **Glutamine** used for **ammoniagenesis**: helps eliminate H⁺ ions and maintain pH. - **Arginine** used in **urea cycle (minor)** and **NO synthesis**.
Answer: - **Erythropoietin**: Stimulates RBC production. - **Renin**: Activates RAAS → BP regulation. - **1α-hydroxylase**: Converts 25(OH)D to **active Vitamin D (calcitriol)**.
Answer: - Inactivation of **insulin, aldosterone**, and other peptide hormones.
Answer: - RBCs rely solely on **anaerobic glycolysis** for ATP.
Answer: - Produces **2 ATP/glucose**. - Maintains **Na⁺/K⁺ ATPase** and **membrane integrity**.
Answer: - Generates **NADPH** → reduces **glutathione**. - Protects against **oxidative damage**. - Defect → **G6PD deficiency** → hemolysis.
Answer: - Converts **Fe³⁺ → Fe²⁺** in hemoglobin. - Prevents formation of **methemoglobin**, which cannot bind oxygen.
Answer: - Generates **2,3-Bisphosphoglycerate (2,3-BPG)**. - Decreases Hb’s oxygen affinity → **enhances oxygen release to tissues**.
Answer: - Defects in enzymes (e.g., **PK, G6PD**) cause **hemolytic anemia**. - Abnormal metabolism affects oxygen delivery, cell survival, and blood function. - Enzymes used in clinical diagnosis can be classified based on:a) **Absolute specificity** – enzymes that act on only one substrate (e.g., urease acts only on urea).b) **Group specificity** – enzymes that act on molecules with a specific functional group (e.g., alcohol dehydrogenase acts on alcohols).c) **Linkage specificity** – enzymes that act on a specific type of bond regardless of the rest of the molecular structure (e.g., esterase acts on ester bonds).d) **Stereochemical specificity** – enzymes that act on specific isomers of a compound (e.g., L-lactate dehydrogenase acts on L-lactate, not D-lactate). a) **Ensures accuracy and reliability** of laboratory results.b) **Detects analytical errors** early to prevent reporting of incorrect data.c) **Maintains consistency** of test results over time.d) **Supports accreditation** and compliance with laboratory standards (e.g., ISO 15189). a) **Prostate-Specific Antigen (PSA)** – Prostate cancerb) **Alpha-Fetoprotein (AFP)** – Hepatocellular carcinoma, germ cell tumorsc) **CA-125** – Ovarian cancerd) **Carcinoembryonic Antigen (CEA)** – Colorectal cancer, pancreatic cancer - a) **Use of quality control (QC) charts** – e.g., Levey-Jennings plots to detect shifts or trendsb) **Proficiency testing (external quality assessment)** – comparing lab results with peer groupsc) **Repetition of tests using control materials** – to verify consistent performanced) **Instrument calibration and maintenance logs** – identifying instrument-related drifts over time - **Discuss acute renal failure, highlighting possible causes and management strategies.** **Definition:** - Acute Renal Failure (ARF), now commonly referred to as **Acute Kidney Injury (AKI)**, is a sudden decline in renal function, leading to decreased glomerular filtration rate (GFR), retention of waste products, fluid imbalance, and electrolyte disturbances. **Causes of Acute Renal Failure:****a) Prerenal causes** (due to decreased renal perfusion): - Hypovolemia (e.g., hemorrhage, dehydration) - Heart failure - Sepsis or shock - Renal artery stenosis **b) Intrarenal causes** (due to damage within the kidney): - Acute tubular necrosis (due to toxins or ischemia) - Glomerulonephritis - Interstitial nephritis - Nephrotoxic drugs (e.g., aminoglycosides, NSAIDs) **c) Postrenal causes** (due to obstruction to urine flow): - Ureteral obstruction (e.g., stones, tumors) - Enlarged prostate (BPH) - Urethral stricture **Management Strategies:** - **Identify and treat the underlying cause** (e.g., fluid resuscitation in prerenal causes) - **Monitor and maintain fluid and electrolyte balance** - **Discontinue nephrotoxic drugs** - **Use diuretics cautiously** (e.g., furosemide) - **Dialysis** if indicated (e.g., refractory hyperkalemia, acidosis, volume overload, uremic symptoms) - **Monitor renal function parameters** (e.g., serum creatinine, urine output) - **Nutritional support** – avoid excess protein intake to reduce uremia **Discuss FIVE key parameters tested in a clinical sample and their clinical significance.** **a) Glucose:** - Tested in blood or urine - Clinical Significance: Screening and monitoring of **diabetes mellitus**, hypoglycemia, and stress-related hyperglycemia **b) Creatinine:** - Tested in serum or plasma - Clinical Significance: Reflects **renal function**; elevated levels indicate impaired kidney function **c) Alanine aminotransferase (ALT):** - Tested in serum - Clinical Significance: Marker for **liver cell injury**; elevated in hepatitis and other liver diseases **d) Hemoglobin (Hb):** - Tested in whole blood - Clinical Significance: Assesses for **anemia**, polycythemia, or blood loss **e) C-reactive protein (CRP):** - Tested in serum or plasma - Clinical Significance: Marker of **inflammation or infection**; elevated in acute and chronic inflammatory conditions **a) Urinalysis (Dipstick Test):** - Measures **pH**, **protein**, **glucose**, **ketones**, **blood**, **leukocyte esterase**, and **nitrites**. - **Clinical Significance:** Helps detect **proteinuria**, **hematuria**, **glucosuria**, and **infections**. Proteinuria may indicate **glomerular damage**. **b) Urine Protein-to-Creatinine Ratio (UPCR):** - Measures protein excretion in a spot urine sample, normalized to creatinine. - **Clinical Significance:** Detects **proteinuria** accurately without 24-hour collection; useful in assessing **chronic kidney disease (CKD)** progression. **c) Urine Specific Gravity and Osmolality:** - Specific gravity measures urine concentration; osmolality assesses solute concentration. - **Clinical Significance:** Assesses the kidney’s **concentrating ability**; abnormal in **tubular disorders**, **diabetes insipidus**, or **dehydration**. **d) Urine Microscopy:** - Examines urinary sediment for **casts**, **RBCs**, **WBCs**, **epithelial cells**, **bacteria**, and **crystals**. - **Clinical Significance:****RBC casts** suggest **glomerulonephritis** - **WBC casts** indicate **pyelonephritis** - **Granular or waxy casts** suggest **chronic kidney disease** **a) Antithyroid Medications:** - **Methimazole** and **propylthiouracil (PTU)** inhibit thyroid hormone synthesis. - PTU also blocks peripheral conversion of T4 to T3. - Used as first-line treatment or to prepare for surgery/radioactive iodine. **b) Beta-Blockers (e.g., Propranolol):** - Control symptoms like **tachycardia**, **tremors**, and **anxiety**. - Propranolol also inhibits peripheral T4 to T3 conversion. **c) Radioactive Iodine Therapy (RAI):** - Oral administration of I-131 selectively destroys overactive thyroid tissue. - Most commonly used for **Graves’ disease** and **toxic multinodular goiter**. - May lead to **hypothyroidism**, requiring levothyroxine replacement. **d) Surgery (Thyroidectomy):** - Partial or total removal of the thyroid gland. - Indicated in cases of **large goiters**, **thyroid cancer**, **pregnancy intolerance to medication**, or **failed medical therapy**. - Requires lifelong thyroid hormone replacement in total thyroidectomy. **e) Adjunctive Therapy:** - **Glucocorticoids** may be used in thyroid storm to reduce T4 to T3 conversion. - **Iodine solutions** (e.g., Lugol's iodine) temporarily inhibit hormone release (used in acute situations pre-surgery). - **Diagnostic markers**: Certain proteins are elevated in specific cancers, helping in early diagnosis.*Example: Prostate-Specific Antigen (PSA) in prostate cancer.* - **Prognostic markers**: Protein levels can indicate disease severity or likely outcome.*Example: HER2/neu overexpression in breast cancer signals poor prognosis.* - **Monitoring treatment response**: Declining protein levels post-treatment may indicate therapeutic success.*Example: Alpha-fetoprotein (AFP) in hepatocellular carcinoma.* - **Detecting recurrence**: Rising levels post-treatment can signal relapse.*Example: CA-125 in ovarian cancer.* - **Diagnosis**: Aid in confirming or ruling out diseases (e.g., glucose test for diabetes). - **Monitoring**: Track disease progression and treatment response (e.g., HbA1c in diabetes). - **Prognosis and management**: Guide therapy decisions and assess risk (e.g., troponin in myocardial infarction). - **Clinical inconsistency**: Results don’t match patient symptoms or history. - **Repeat testing**: A significant discrepancy between current and previous results. - **Delta checks**: Comparing current values with past results to identify unlikely changes. - **Communication with lab**: Confirming critical or unexpected values through direct discussion or repeat sampling. - **Methanol Metabolism in the Liver**:Methanol is **oxidized by alcohol dehydrogenase (ADH)** into **formaldehyde**, which is then rapidly converted by **aldehyde dehydrogenase (ALDH)** into **formic acid**, the primary toxic agent. **Biochemical Reactions:****Methanol → Formaldehyde***(Enzyme: Alcohol Dehydrogenase)* - **Formaldehyde → Formic acid***(Enzyme: Aldehyde Dehydrogenase)* - **Toxic Mechanism**:**Formic acid** accumulates and causes:**Severe metabolic acidosis** (↓ blood pH) - **Inhibition of mitochondrial cytochrome c oxidase** → impaired ATP production - **Optic nerve toxicity** → can lead to **blindness** - **Clinical Manifestations**:Headache, dizziness, visual disturbances ("snowfield vision"), nausea - May progress to coma, blindness, or death if untreated - **Assessment of cardiovascular risk**: Elevated LDL-C and total cholesterol are linked to atherosclerosis and coronary artery disease. - **Monitoring therapy**: Used to evaluate the effectiveness of lipid-lowering treatments (e.g., statins). - **Diagnosing lipid disorders**: Helps identify conditions like familial hypercholesterolemia or metabolic syndrome. - **Increased mitochondrial density**: Enhances aerobic ATP production in muscle cells. - **Enhanced capillarization**: Improves oxygen and nutrient delivery to muscle fibers. - **Improved oxidative enzyme activity**: Boosts the efficiency of aerobic metabolic pathways (e.g., TCA cycle enzymes). - **Alcohol Dehydrogenase (ADH) Pathway***(Primary route in liver)*:Ethanol → Acetaldehyde (via **ADH**) - Acetaldehyde → Acetate (via **ALDH**) - **Microsomal Ethanol Oxidizing System (MEOS)***(Inducible by chronic alcohol use)*:Enzyme: **Cytochrome P450 2E1 (CYP2E1)** - Ethanol is oxidized to acetaldehyde, consuming NADPH and generating ROS. - **Catalase Pathway***(Minor contribution, especially in peroxisomes)*:Uses **H₂O₂** to oxidize ethanol → Acetaldehyde (via **catalase**) - **Lactate recycling**: During anaerobic glycolysis in muscles, **lactate** is produced and transported to the liver. - **Gluconeogenesis** in the liver: Lactate is converted back to **glucose**, using ATP. - **Glucose returned to muscle**: Maintains blood glucose levels during intense activity or fasting, especially important for muscles and the brain. A. **Definition of Thermogenesis** - Thermogenesis is the **physiological production of heat**, primarily to maintain core body temperature, especially in cold environments. B. **Types of Thermogenesis** - **Basal Thermogenesis**Heat generated from basic metabolic functions at rest. - **Activity-induced Thermogenesis**Includes heat from **voluntary** (exercise) and **involuntary muscle activity** (shivering). - **Diet-induced Thermogenesis (DIT)**Also called **specific dynamic action**: Heat produced after food intake due to digestion, absorption, and nutrient metabolism. - **Non-Shivering Thermogenesis (NST)**Occurs **without muscle contractions**. - Primarily in **brown adipose tissue (BAT)** via **uncoupling proteins** (especially UCP1). - Significant in **infants** and **hibernating animals**, less but still present in adult humans. --- C. **Mechanism of Non-Shivering Thermogenesis** - **Brown adipose tissue (BAT)** contains numerous **mitochondria** with **uncoupling protein 1 (UCP1)**. - **UCP1** allows **protons** to re-enter the mitochondrial matrix without generating ATP. - This **"uncouples" oxidative phosphorylation**, leading to the release of **heat** instead of ATP. --- D. **Regulation of Non-Shivering Thermogenesis** - **Cold exposure**Detected by skin thermoreceptors → hypothalamus → activates sympathetic nervous system. - **Sympathetic Nervous System Activation****Norepinephrine** is released → binds to **β3-adrenergic receptors** on brown adipocytes. - **cAMP Pathway Activation**Activates **protein kinase A (PKA)** → stimulates **lipolysis** → release of free fatty acids. - **Free Fatty Acids (FFAs)**Act as both **fuel** and **activators** of **UCP1**, driving proton leak and heat generation. --- E. **Hormonal Regulation** - **Thyroid hormones (especially T3)**: Increase **mitochondrial biogenesis**, **UCP1 expression**, and **basal metabolic rate**. - **Leptin**: Enhances thermogenesis via **central nervous system** pathways. - **Insulin**: May indirectly influence BAT activity by modulating substrate availability. --- F. **Clinical Relevance** - **Obesity and metabolism**: Activation of BAT is being explored as a target for obesity treatment. - **Hypothyroidism**: Reduced thermogenesis, leading to cold intolerance. - **Neonatal thermoregulation**: Infants rely heavily on NST due to limited muscle mass for shivering. A. **Cardiac Tissue Enzymes** - **Creatine Kinase-MB (CK-MB)**Specific for **cardiac muscle damage** (e.g., myocardial infarction). - Rises within 4–6 hrs; peaks at 24 hrs. - **Troponin I/T (cTnI, cTnT)****Most specific and sensitive marker** for myocardial injury. - Elevated for 7–10 days post-infarction. --- B. **Liver Enzymes** - **Alanine Transaminase (ALT)**Specific to **hepatocytes**. - Elevated in **hepatitis, liver necrosis**. - **Aspartate Transaminase (AST)**Found in **liver, heart, and muscle**. - AST:ALT ratio helps differentiate **alcoholic vs viral hepatitis*